Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY Trial

Background: Anthracycline (ANT) is often used for breast cancer treatment but its clinical use is limited by cardiotoxicity (CTX). CECCY trial demonstrated that the β-blocker carvedilol (CVD) could attenuate myocardial injury secondary to ANT. Mieloperoxydase (MPO) is a biomarker of oxidative stress...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanderley Jr., Mauro Rogério de Barros, Ávila, Mônica Samuel, Fernandes-Silva, Miguel Morita, Cruz, Fátima das Dores, Brandão, Sara Michelly Gonçalves, Rigaud, Vagner Oliveira Carvalho, Hajjar, Ludhmila Abrahão, Filho, Roberto Kalil, Cunha-Neto, Edécio, Bocchi, Edimar Alcides, Ayub-Ferreira, Silvia Moreira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789241/
https://www.ncbi.nlm.nih.gov/pubmed/35087624
http://dx.doi.org/10.18632/oncotarget.28182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789241/
https://www.ncbi.nlm.nih.gov/pubmed/35087624
http://dx.doi.org/10.18632/oncotarget.28182

Ejemplares similares